Your browser doesn't support javascript.
loading
MEX-PD: A National Network for the Epidemiological & Genetic Research of Parkinson's Disease.
Lázaro-Figueroa, Alejandra; Reyes-Pérez, Paula; Morelos-Figaredo, Eugenia; Guerra-Galicia, Carlos M; Estrada-Bellmann, Ingrid; Salinas-Barboza, Karla; Matuk-Pérez, Yamil; Gandarilla-Martínez, Nadia A; Caballero-Sánchez, Ulises; Flores-Ocampo, Victor; Montés-Alcántara, Pablo; Espinosa-Méndez, Ian M; Moral, Alejandra Zayas-Del; Gaspar-Martínez, Edith; Vazquez-Guevara, Damaris; Rodríguez-Violante, Mayela; Inca-Martinez, Miguel; Mata, Ignacio F; Alcauter, Sarael; Rentería, Miguel E; Medina-Rivera, Alejandra; Ruiz-Contreras, Alejandra E.
Affiliation
  • Lázaro-Figueroa A; Lab. Neurogenómica Cognitiva, Unidad de Investigación en Psicobiología y Neurociencias, Coord. Psicobiología y Neurociencias, Fac. Psicología, Universidad Nacional Autónoma de México (UNAM), Ciudad de México, México.
  • Reyes-Pérez P; Laboratorio Internacional de Investigación sobre el Genoma Humano, Universidad Nacional Autónoma de México, Querétaro, México.
  • Morelos-Figaredo E; Hospital Regional ISSSTE, Morelia, México.
  • Guerra-Galicia CM; Neurociencias PRISMA AC, San Luis Potosí, México.
  • Estrada-Bellmann I; Movement Disorders Clinic, Neurology Division, Internal Medicine Department, University Hospital "Dr. José E. González", Universidad Autónoma de Nuevo León, Monterrey. Mexico.
  • Salinas-Barboza K; Hospital General de México, Ciudad de México, México.
  • Matuk-Pérez Y; Facultad de Medicina, Universidad Autónoma de Querétaro. Unidad de Neurociencias, Hospital Ángeles Centro Sur.
  • Gandarilla-Martínez NA; Centro Neurológico del Centro Médico ABC, Campus Santa Fe, Ciudad de México, México.
  • Caballero-Sánchez U; Lab. Neurogenómica Cognitiva, Unidad de Investigación en Psicobiología y Neurociencias, Coord. Psicobiología y Neurociencias, Fac. Psicología, Universidad Nacional Autónoma de México (UNAM), Ciudad de México, México.
  • Flores-Ocampo V; Laboratorio Internacional de Investigación sobre el Genoma Humano, Universidad Nacional Autónoma de México, Querétaro, México.
  • Montés-Alcántara P; Lab. Neurogenómica Cognitiva, Unidad de Investigación en Psicobiología y Neurociencias, Coord. Psicobiología y Neurociencias, Fac. Psicología, Universidad Nacional Autónoma de México (UNAM), Ciudad de México, México.
  • Espinosa-Méndez IM; Instituto de Neurobiología, Universidad Nacional Autónoma de México, Querétaro, México.
  • Moral AZ; Centro de Ciencias Genómicas, Universidad Nacional Autónoma de México, Cuernavaca, Morelos, México.
  • Gaspar-Martínez E; Instituto de Neurobiología, Universidad Nacional Autónoma de México, Querétaro, México.
  • Vazquez-Guevara D; Facultad de Medicina y Psicología. Universidad Autónoma de Baja California.
  • Rodríguez-Violante M; Laboratorio Clínico de Enfermedades Neurodegenerativas. Instituto Nacional de Neurología y Neurocirugía, Ciudad de Mexico, Mexico.
  • Inca-Martinez M; Genomic Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland, OH.
  • Mata IF; Genomic Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland, OH.
  • Alcauter S; Instituto de Neurobiología, Universidad Nacional Autónoma de México, Querétaro, México.
  • Rentería ME; School of Biomedical Sciences, Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia.
  • Medina-Rivera A; Mental Health & Neuroscience Program, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
  • Ruiz-Contreras AE; Laboratorio Internacional de Investigación sobre el Genoma Humano, Universidad Nacional Autónoma de México, Querétaro, México.
medRxiv ; 2023 Aug 31.
Article in En | MEDLINE | ID: mdl-37693616
ABSTRACT

Background:

Parkinson's Disease (PD) has a complex etiology, involving genetic and environmental factors. Most of our current understanding of the disease comes from studies in populations with mostly European ancestry, representing challenges in generalizing findings to other populations with different genetic, social, and environmental contexts. There are scarce studies focused in Latin American populations. The Mexican population is genetically diverse because its admixture from Native American, European, and African ancestries, coupled with the unique environmental conditions, stressing the relevance of establishing genetic studies in this population. Thus, we have established the Mexican Parkinson's Research Network (MEX-PD), a consortium to research the clinical, genetical, environmental, and neurophysiological bases of the phenotypic diversity in Mexican PD patients.

Objectives:

Describing how MEX-PD was established, the methods and instruments and presenting the first results.

Methods:

Patients and controls were recruited from medical centers in 20 states of Mexico. Initial recruitment included neurological evaluation, cognitive assessment, and DNA collection.

Results:

MEX-PD has registered 302 controls and 262 PD patients with a mean age of diagnosis of 61 years (SD=10.86). There were 19.8% PD patients identified with early onset. Levodopa was the most common pharmacological treatment.

Conclusions:

MEX-PD contributes to understand PD nationally. The information gathered here will allow us to understand the prevalence of mental health, neurological symptoms, and cognitive function in the PD Mexican population and how genetical and environmental factors contributes to those outcomes. These will advocate for personalized treatments and improving quality of life in the Mexican population.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies / Risk_factors_studies Aspects: Patient_preference Language: En Journal: MedRxiv Year: 2023 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies / Risk_factors_studies Aspects: Patient_preference Language: En Journal: MedRxiv Year: 2023 Document type: Article
...